Strategic objectives

• Advance in the physiopathological knowledge of the ischemia/reperfusion lesion in the context of renal transplantation via translational research from the experimental to the clinical field.
• Identify biomarkers that enable the viability and function of the graft to be predicted after renal transplantation.
• Advance in the development of pharmacological modulation models of the ischemia-reperfusion lesion during renal preservation in perfusion devices.
• Evaluate the diagnostic profitability and therapeutic efficacy of new diagnostic and treatment techniques in prostate cancer: fusion guided MRI biopsy and ultrasound via guided navigation systems, prostate cancer focal ablation techniques and intraoperative neurostimulation of neurovascular bundles in prostate surgery.
• Actively participate in multi-centre studies for the evaluation of new molecules in the treatment of prostate cancer.
• Actively participate in multi-centre studies and collaborative groups for the study and treatment of functional pathology and oncological bladder.
• Search for biomarkers that predict response to treatment and disease recurrence, as well as molecularly characterize the neoplasia and tumor microenvironment in renal and urothelial cancer.

Research lines

• Renal transplantation and preservation in the experimental and clinical fields.
• Prostate cancer: diagnostic and therapeutic innovation.
• Diagnostic and therapeutic innovation in bladder pathology.
• Diagnostic and therapeutic innovation in renal and urothelial tumor.